Somewhat Positive Press Coverage Somewhat Unlikely to Affect Evoke Pharma (EVOK) Stock Price

News coverage about Evoke Pharma (NASDAQ:EVOK) has been trending somewhat positive on Friday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Evoke Pharma earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 48.5954779022916 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of Evoke Pharma (NASDAQ EVOK) traded up $0.18 during trading on Friday, hitting $2.71. The stock had a trading volume of 31,800 shares, compared to its average volume of 74,217. The stock has a market capitalization of $41.00, a P/E ratio of -2.88 and a beta of 1.09. Evoke Pharma has a 12-month low of $2.19 and a 12-month high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.13). During the same period in the previous year, the firm earned ($0.29) earnings per share. equities analysts forecast that Evoke Pharma will post -1 earnings per share for the current fiscal year.

EVOK has been the topic of several recent research reports. Seaport Global Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Friday, October 6th. Zacks Investment Research upgraded Evoke Pharma from a “strong sell” rating to a “hold” rating in a report on Thursday, October 12th. Northland Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Wednesday, October 18th. FBR & Co reiterated a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Thursday, October 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Evoke Pharma in a report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. Evoke Pharma presently has a consensus rating of “Buy” and an average price target of $9.00.

WARNING: This piece of content was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://ledgergazette.com/2018/01/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-evoke-pharma-evok-stock-price.html.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply